Fuan Pharmaceutical(SZ:300194) Sou Hu Cai Jing·2025-08-15 10:08Core Viewpoint - Fuan Pharmaceutical (300194) has experienced a significant decline in revenue and net profit in the latest quarterly report, indicating potential challenges in its financial performance moving forward [1]. Financial Performance - As of the first quarter of 2025, the company reported total revenue of 468 million yuan, a year-on-year decrease of 42.22% [1]. - The net profit attributable to shareholders was 69.05 million yuan, down 43.63% year-on-year [1]. - The non-recurring net profit was 65.68 million yuan, reflecting a decrease of 43.80% compared to the previous year [1]. - The company's liquidity ratios are as follows: current ratio at 2.011 and quick ratio at 1.269, indicating a strong liquidity position [1]. - The asset-liability ratio stands at 26.84%, suggesting a relatively low level of debt [1]. Market Activity - The stock closed at 4.9 yuan, with a slight decline of 0.41% [1]. - The trading volume was 882,200 hands, with a total transaction value of 428 million yuan [1]. - The net inflow of main funds was 10.03 million yuan, accounting for 2.34% of the transaction amount [1]. - Large orders saw a net inflow of 7.57 million yuan, while small orders experienced a net outflow of 22.50 million yuan [1]. Company Overview - Fuan Pharmaceutical was established in 2004 and is based in Chongqing, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of approximately 1.19 billion yuan and a paid-in capital of 173.42 million yuan [1]. - The legal representative of the company is Wang Tianxiang [1]. Investment and Intellectual Property - Fuan Pharmaceutical has made investments in 17 external enterprises and participated in four bidding projects [2]. - The company holds 22 trademark registrations and 21 patents, along with 18 administrative licenses [2].